Aldevron Unveils Next-Generation Alchemy™ Cell-Free DNA Technology for Research Grade Applications
Aldevron has launched Alchemy™, a revolutionary cell-free DNA technology for research grade applications. This innovative technology cuts linear DNA manufacturing time by over 50 percent while producing cleaner, safer DNA templates for mRNA synthesis.
The technology utilizes rolling circle amplification for DNA template production, eliminating the need for cells in DNA amplification. Key benefits include faster turnaround times, lower endotoxin levels, reduced host cell-derived impurities, and high-quality control specifications. The research grade version is currently available to support development and preclinical programs, with a cGMP offering planned for 2025 to support clinical applications.
Aldevron ha lanciato Alchemy™, una tecnologia rivoluzionaria di DNA priva di cellule per applicazioni di ricerca. Questa tecnologia innovativa riduce il tempo di produzione del DNA lineare di oltre 50 percento mentre produce template di DNA più puliti e sicuri per la sintesi dell'mRNA.
La tecnologia utilizza l'amplificazione a cerchio rotante per la produzione di template di DNA, eliminando la necessità di cellule nell'amplificazione del DNA. I principali vantaggi includono tempi di consegna più rapidi, livelli di endotossine più bassi, impurità derivate da cellule ospiti ridotte e specifiche di controllo qualità elevate. La versione di ricerca è attualmente disponibile per supportare lo sviluppo e i programmi preclinici, con un offerta cGMP pianificata per il 2025 per supportare le applicazioni cliniche.
Aldevron ha lanzado Alchemy™, una tecnología revolucionaria de ADN libre de células para aplicaciones de investigación. Esta innovadora tecnología reduce el tiempo de fabricación de ADN lineal en más de 50 por ciento, produciendo plantillas de ADN más limpias y seguras para la síntesis de ARNm.
La tecnología utiliza amplificación en círculo rodante para la producción de plantillas de ADN, eliminando la necesidad de células en la amplificación de ADN. Los principales beneficios incluyen tiempos de respuesta más rápidos, niveles de endotoxinas más bajos, reducción de impurezas derivadas de células huésped y especificaciones de control de calidad elevadas. La versión de investigación está actualmente disponible para apoyar el desarrollo y programas preclínicos, con una oferta cGMP planificada para 2025 para apoyar aplicaciones clínicas.
Aldevron은 연구 등급 응용 프로그램을 위한 세포 없는 DNA 기술인 Alchemy™를 출시했습니다. 이 혁신적인 기술은 선형 DNA 제조 시간을 50% 이상 단축시키면서 mRNA 합성을 위한 보다 깨끗하고 안전한 DNA 템플릿을 생성합니다.
이 기술은 DNA 템플릿 생산에 롤링 서클 증폭을 사용하여 DNA 증폭에서 세포의 필요성을 제거합니다. 주요 이점에는 더 빠른 처리 시간, 낮은 내독소 수준, 세포 유래 불순물 감소 및 높은 품질 관리 규격이 포함됩니다. 연구 등급 버전은 현재 개발 및 전임상 프로그램을 지원하기 위해 제공되며, 2025년에 cGMP 제공이 계획되어 임상 응용 프로그램을 지원할 것입니다.
Aldevron a lancé Alchemy™, une technologie révolutionnaire d'ADN sans cellule pour les applications de recherche. Cette technologie innovante réduit le temps de fabrication de l'ADN linéaire de plus de 50 pour cent tout en produisant des modèles d'ADN plus propres et plus sûrs pour la synthèse d'ARNm.
La technologie utilise l'amplification en cercle roulant pour la production de modèles d'ADN, éliminant ainsi la nécessité de cellules dans l'amplification de l'ADN. Les principaux avantages comprennent des délais de traitement plus rapides, des niveaux d'endotoxines plus bas, des impuretés dérivées des cellules hôtes réduites, et des spécifications de contrôle de qualité élevées. La version de recherche est actuellement disponible pour soutenir le développement et les programmes précliniques, avec une offre cGMP prévue pour 2025 afin de soutenir les applications cliniques.
Aldevron hat Alchemy™ eingeführt, eine revolutionäre zellfreie DNA-Technologie für Forschungsanwendungen. Diese innovative Technologie verkürzt die Herstellungszeit für lineare DNA um über 50 Prozent und produziert sauberere, sicherere DNA-Vorlagen für die mRNA-Synthese.
Die Technologie nutzt die Rolling-Circle-Amplifikation zur DNA-Vorlagenproduktion, wodurch die Notwendigkeit von Zellen bei der DNA-Vermehrung entfällt. Zu den Hauptvorteilen gehören schnellere Durchlaufzeiten, niedrigere Endotoxinwerte, reduzierte aus Wirtzellen stammende Verunreinigungen und hohe Qualitätskontrollspezifikationen. Die Forschungsgradversion ist derzeit verfügbar, um Entwicklungs- und präklinische Programme zu unterstützen, mit einem cGMP-Angebot, das für 2025 geplant ist, um klinische Anwendungen zu unterstützen.
- Reduces DNA manufacturing time by 50%
- Eliminates host cell protein, genomic DNA, and endotoxin contamination
- Planned expansion to cGMP grade in 2025 for clinical applications
- None.
Insights
Aldevron's new Alchemy™ technology represents a significant manufacturing breakthrough in the mRNA supply chain. The 50% reduction in DNA template production time directly impacts the economics and scalability of mRNA therapeutics development. The cell-free approach eliminates major bottlenecks in traditional plasmid DNA production, notably removing host cell proteins, genomic DNA contamination and endotoxins that typically require extensive downstream purification.
The rolling circle amplification method is particularly noteworthy as it enables exponential DNA synthesis without the biological constraints of bacterial fermentation. This translates to faster turnaround times for pharmaceutical companies developing mRNA-based therapies, potentially accelerating the development pipeline from discovery to clinical trials.
For Danaher (DHR), which acquired Aldevron in 2021 for
This technological advancement positions Danaher to capture a larger share of the rapidly expanding mRNA therapeutics market. The timing is strategic, as the industry shifts from COVID-19 vaccine production to broader mRNA applications in oncology, rare diseases and personalized medicine. The key competitive advantages of faster production time and higher purity directly address critical pain points in the current mRNA development process.
The planned progression to cGMP manufacturing capability indicates a well-structured commercialization strategy that could generate substantial recurring revenue streams. Based on current market dynamics, this technology could help secure long-term contracts with major pharmaceutical companies investing in mRNA platforms. The reduction in manufacturing time and improved purity profile could lead to better margins and potentially higher pricing power for Aldevron's services.
Aldevron’s Alchemy™ is an exclusive cell-free DNA technology which cuts research grade linear DNA manufacturing time by over 50 percent, accelerating mRNA development projects with cleaner, safer DNA templates. (Graphic: Business Wire)
Alchemy cell-free DNA technology is now available at research grade, providing researchers with a faster, more efficient method to produce high-quality DNA templates. This technology is designed to support development and preclinical programs, with a future cGMP offering expected to launch in 2025 to support clinical applications and beyond.
“Alchemy is Aldevron’s exclusive cell-free DNA technology which cuts research grade linear DNA manufacturing time by over 50 percent, accelerating mRNA development projects with cleaner, safer DNA templates,” said Venkata Indurthi, Chief Scientific Officer for Aldevron. “This is a reliable and efficient foundation for mRNA synthesis that also delivers higher purity without host cell protein, gDNA, or endotoxin. We are delivering on our mission is to be the engine of innovation for genomic medicine pioneers to ensure they can maintain a competitive edge.”
Key Benefits of Alchemy Technology:
- Faster Turnaround: The Alchemy process significantly reduces production timelines, allowing researchers to accelerate their projects and meet deadlines faster.
- Low Endotoxin and Other Cell-Derived Impurities: By eliminating the use of cells in the DNA amplification process, the technology ensures minimal endotoxin levels and mitigates the introduction of other host cell-derived impurities, resulting in higher purity DNA and mRNA downstream.
- Comparable Quality Control Specifications: mRNA produced using Alchemy technology meets stringent quality control specifications, ensuring the highest standards of purity and performance.
Aldevron's proprietary cell-free DNA manufacturing process, utilizing rolling circle amplification, enables the rapid production of linear DNA templates. This method supports the swift screening of mRNA constructs and the turnaround of candidate selection within the clients’ workflow, further expediting client manufacturing timelines.
For more information about Alchemy cell-free DNA technology and how it can enhance the mRNA production process, visit aldevron.com.
About Aldevron
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, enzymes, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121761284/en/
Aldevron
Ellen Shafer, Senior Director of Communications
ellen.shafer@aldevron.com
701-219-0333
Source: Aldevron
FAQ
What is Aldevron's new Alchemy™ technology and how does it improve DNA manufacturing?
When will Aldevron's Alchemy™ technology be available for clinical applications?
What are the key benefits of Aldevron's Alchemy™ technology?
How does Alchemy™ technology improve DNA template purity?
